TechDogs-"Establishment Of HD Immune And Publication Of The Latest Preclinical Data"

BioTechnology

Establishment Of HD Immune And Publication Of The Latest Preclinical Data

By Business Wire

Business Wire
Overall Rating

VIENNA--(  )-- HD Immune GmbH (HDI), a privately held biotechnology company developing novel antibody treatments for Huntington's disease, is a joint venture between Dr. Stefan Bartle and Dr. Lionel Wightman. Two people announced that they will start a business as founders. HDI acquired the Huntington's disease program patents and assets from AFFiRiS AG. HDI also completed a pre-seed funding round with an Austrian business angel and secured a pre-seed grant from Austria Bildshafts Services (AWS). Additionally, HDI has successfully applied to the Comet24 program of the Austrian Center for Industrial Biotechnology (acib), enabling collaboration with the Institute of Molecular Biotechnology (BOKU, Vienna University of Natural Resources and Life Sciences) on HDI's research programs. We announced what happened.

Stefan Bartle, CEO of HDI, said: “With the acquisition of the Huntington's disease program that I previously developed at AFFiRiS AG, HD Immune will be able to move from the get-go to an unprecedented step to demonstrate the therapeutic efficacy of our lead monoclonal antibody C6-17 in a transgenic model of Huntington's disease. This means that we have excellent preclinical data, which we have just recently published.We are currently working on a drug that aims to slow the progression of Huntington's disease and improve the quality of life for patients. We are proceeding with the humanization process of this antibody in order to develop a treatment for the mutant huntingtin protein.Currently, there are no treatments that can directly treat the mutant huntingtin protein."

HD Immune's new preclinical study report can be downloaded from our webpage www.hdimmune.com .

HD immunity and Huntington's disease

Huntington's disease (HD) is a fatal neurodegenerative disease that usually begins clinically in the fourth decade of life and progresses to severe neurological and psychiatric exacerbations. HD is a rare single-gene disease in which mutated huntingtin protein (mtHTT), which is structurally altered due to genetic mutations, forms aggregates in the brain.

HD Immune is developing antibodies that target this mutant protein and remove it from the body. HDI's proprietary lead antibody, mAB C6-17, reduced mtHTT in the blood, organs, and central nervous system, as well as improved exercise performance in transgenic mice expressing the human mutant protein. Based on these results, HD Immune plans to further develop antibodies for human treatment to alleviate symptoms in patients.

The official version of this press release is the original language version. Translated language versions are provided for the convenience of the reader and have no legal effect. When using a translated language version as a document, please compare it with the original language version, which is the only legally enforceable version.

Contacts

HD Immune GmbH
office@hdimmune.com
www.hdimmune.com

First published on Wed, Jan 24, 2024

Liked what you read? That’s only the tip of the tech iceberg!

Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!

Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.

Dive into TechDogs' treasure trove today and Know Your World of technology like never before!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs’ members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs’ Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs’ site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.

Tags:

HD Immune GmbH Developing Novel Antibody Austria Bildshafts Services (AWS) Huntington's Disease (HD) Mutated Huntingtin Protein (mtHTT)

References:

Join The Discussion

- Promoted By TechDogs -

Salesforce Made Easy With Techila
  • Dark
  • Light